Coronavirus: Russian vaccine Sputnik V has demonstrated …

The Russian coronavirus vaccine, Sputnik V, has been shown to be more than 95% effective. According to a statement released by the Gamaleya Center and the Russian Direct Investment Fund (FIDR), the vaccine achieved this percentage of effectiveness 42 days after the first dose. In addition, they announced that the cost of the vaccine will be less than $ 10.

Based on preliminary data from the second interim analysis of the phase 3 clinical trial, the effectiveness of the Russian vaccine after 28 days is 91.4%. The efficacy evaluation was carried out on 18,794 volunteers, 28 days after receiving the first dose and seven after the second dose of vaccine or placebo.

However, preliminary data on volunteers on day 42 after the first dose (equivalent to 21 days after the second dose), when they have already formed a stable immune response, indicate that the vaccine efficacy rate is greater than 95%.

The Gamaleya Center reported that “The uniqueness of the Russian vaccine is the use of two different vectors based on human adenovirus, which allows a stronger immune response and longer term compared to vaccines using the same vector for two doses “.

In addition, Russian investigators indicated in the press release that So far, there have been no “unexpected adverse events during testing”.

Currently, 40,000 volunteers participate in double-blind, randomized, placebo-controlled phase III clinical study of the Sputnik V vaccine after registration in Russia, of which more than 22,000 volunteers were vaccinated with the first dose and more than 19,000 volunteers with the first and second doses.

Intermediate research data will be published by the Centro Gamaleya team in one of the leading international peer-reviewed medical journals. After the completion of the phase 3 clinical trials, the Center will provide access to the full clinical report.

A vaccine for less than $ 10

FIDR emphasized that the price of Sputnik V will be less than $ 10 for a dose. It would cost much less than vaccines using messenger DNA, such as Moderna and Pfizer.

In addition, Russia has already started production of the dehydrated vaccine, based on freeze-drying technology, which will greatly facilitate its transport to international markets, including regions with difficult access and others with tropical climates.

The first batch of Sputnik V for the foreign market will reach customers in January 2021 on the basis of agreements already signed with foreign partners. Argentina has accepted the arrival of 25 million doses of vaccine.